Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 29, 2020 - Issue 12
Submit an article Journal homepage
1,618
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Genetic prion disease: opportunities for early therapeutic intervention with rigorous pre-symptomatic trials

Peter Hermanna National Reference Center for TSE, University Medical Center Göttingen, Göttingen, Germany;b Department of Neurology, University Medical Center Göttingen, Göttingen, GermanyView further author information
,
Jan C. Kochb Department of Neurology, University Medical Center Göttingen, Göttingen, GermanyView further author information
&
Inga Zerra National Reference Center for TSE, University Medical Center Göttingen, Göttingen, Germany;b Department of Neurology, University Medical Center Göttingen, Göttingen, Germany;c German Center for Neurodegenerative Diseases (DZNE), Göttingen, GermanyCorrespondence[email protected]
View further author information
Pages 1313-1316 | Received 03 Sep 2020, Accepted 15 Oct 2020, Published online: 01 Nov 2020

Reference

  • Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95:13363–13383.
  • Ladogana A, Kovacs GG. Genetic Creutzfeldt-Jakob disease. Handb Clin Neurol. 2018;153:219–242.
  • Appleby BS, Lyketsos CG. Rapidly progressive dementias and the treatment of human prion diseases. Expert Opin Pharmacother. 2011;12:1–12.
  • Forloni G, Roiter I, Tagliavini F. Clinical trials of prion disease therapeutics. Curr Opin Pharmacol. 2019;44:53–60.
  • Vallabh SM, Minikel EV, Schreiber SL, et al. Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurol. 2020;19:361–368.
  • Minikel EV, Vallabh SM, Orseth MC, et al. Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology. 2019;93:e125–e134.
  • Roettger Y, Du Y, Bacher M, et al. Immunotherapy in prion disease. Nat Rev Neurol. 2013;9:98–105.
  • Raymond GJ, Zhao HT, Race B, et al. Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight. 2019;5:e131175.
  • Varges D, Manthey H, Heinemann U, et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry. 2017;88:119–125.
  • Forloni G, Tettamanti M, Lucca U, et al. Preventive study in subjects at risk of fatal familial insomnia: innovative approach to rare diseases. Prion. 2015;9:75–79.
  • Rudge P, Jaunmuktane Z, Adlard P, et al. Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain. 2015;138:3386–3399.
  • Steinacker P, Blennow K, Halbgebauer S, et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016;6:38737.
  • Thompson A, Anastasiadis P, Druyeh R, et al. Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. MedRxiv. 2020. DOI:10.1101/2020.07.27.20157594.
  • Lee H, Rosenmann H, Chapman J, et al. Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. Brain. 2009;132:2680–2687.
  • Cortelli P, Perani D, Montagna P, et al. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain. 2006;129:668–675.
  • Rudge P, Jaunmuktane Z, Hyare H, et al. Early neurophysiological biomarkers and spinal cord pathology in inherited prion disease. Brain. 2019;142:760–770.
  • Hermann P, Laux M, Glatzel M, et al. Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance. Neurology. 2018;9:e331–e338.
  • Rhoads DD, Wrona A, Foutz A, et al. Diagnosis of prion diseases by RT-QuIC results in improved surveillance [published online ahead of print, 2020 Jun 22]. Neurology. 2020. DOI:10.1212/WNL.0000000000010086
  • Vallabh SM, Nobuhara CK, Llorens F, et al. Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. Proc Natl Acad Sci U S A. 2019;116:7793–7798.
  • Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109–119.
  • De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842–856.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.